Cannabis Hyperemesis Syndrome (CHS)
Severe cyclic vomiting triggered by chronic heavy cannabis use; resolves on cessation.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
CHS is real and documented, but most heavy cannabis users don't get it — we don't know why. Stopping cannabis is the only proven fix, but it's hard because people often used it to manage anxiety or pain in the first place. Hot showers feel like magic during an attack but don't treat the underlying problem. Haloperidol works better than anti-nausea drugs in the ER; capsaicin cream shows promise but isn't definitive yet.
Not Medical Advice
This article is educational, not medical advice. If you are vomiting repeatedly, unable to keep fluids down, or experiencing severe abdominal pain, seek immediate medical care. CHS can cause dangerous dehydration, electrolyte disturbances (including hypokalemia), and acute kidney injury Strong evidence[1]. Talk to a clinician before changing treatment for any condition.
Plain-Language Summary
Cannabis hyperemesis syndrome is a paradox: cannabis is widely used (and FDA-approved in synthetic form as dronabinol) to treat nausea, yet in a subset of heavy chronic users it causes severe cyclic vomiting. The syndrome was first formally described in 2004 by Allen and colleagues, who reported nine chronic cannabis users with cyclic vomiting that resolved on cessation and recurred on resumption Strong evidence[2].
CHS typically progresses through three phases Strong evidence[3]:
- Prodromal phase: morning nausea, abdominal discomfort, and fear of vomiting — sometimes lasting for months or years.
- Hyperemetic phase: intense, repeated vomiting (often 5+ times per hour), severe abdominal pain, and the hallmark compulsive hot bathing or showering, which temporarily relieves symptoms.
- Recovery phase: symptoms resolve over days to weeks after stopping cannabis use.
The diagnostic clue most clinicians rely on is the combination of hot-shower behavior and a history of daily cannabis use for at least one year Strong evidence[3][4]. There is no specific laboratory test or biomarker.
What Probably Works
Cannabis cessation is the only intervention with consistent evidence for long-term resolution Strong evidence. Across case series and cohort studies, patients who fully stop using cannabis stop having episodes; those who resume typically relapse [2][3][5].
IV fluid resuscitation and electrolyte replacement are standard supportive care for the dehydration and electrolyte disturbances that accompany acute episodes Strong evidence. This is general emergency medicine, not CHS-specific, but essential when the syndrome is active [1].
Topical capsaicin cream (0.025%–0.1%) applied to the abdomen or back has emerged as a reasonable acute-phase option Weak / limited. The proposed mechanism involves TRPV1 receptor activation, which may mimic the heat-shower relief effect [6]. A 2020 randomized trial (Dean et al.) found capsaicin comparable to ondansetron but did not demonstrate clear superiority over placebo in all endpoints Weak / limited[7].
Haloperidol (a dopamine antagonist) has the strongest emergency-department evidence of any pharmacologic agent. A 2021 randomized controlled trial (Ruberto et al.) compared haloperidol to ondansetron in 33 ED patients with CHS and found haloperidol superior for both pain and nausea reduction Weak / limited[8].
What Might Work
Benzodiazepines (lorazepam) are commonly used in emergency departments and reported in case series to provide symptom relief, possibly via anxiolysis and central antiemetic effects Weak / limited[3]. No high-quality randomized trial exists.
Droperidol, another dopamine antagonist, is used with a mechanism similar to haloperidol, but specific CHS evidence is limited to case reports Weak / limited.
Hot showers and baths reliably abort symptoms during an episode and are diagnostically important, but they are not a treatment — they do not change the underlying course of the syndrome. Prolonged hot bathing has caused significant burns in some patients Anecdote[3].
Cognitive behavioral therapy and motivational interviewing to support cessation are reasonable based on general addiction-medicine evidence, but randomized trials specific to CHS cessation are absent No data.
What Doesn't Work or Has Weak Evidence
Ondansetron (Zofran) — the workhorse antiemetic for chemotherapy and gastroenteritis — performs poorly in CHS. Multiple case series and the Ruberto 2021 RCT show limited efficacy compared to haloperidol Weak / limited[8].
Metoclopramide and promethazine are similarly underwhelming in case series and clinical experience Weak / limited.
Opioids are commonly given for the abdominal pain but do not address the underlying syndrome and risk worsening nausea and fostering dependency Weak / limited.
Proton pump inhibitors and standard gastroenterologic workups (endoscopy, abdominal imaging) typically return unremarkable findings — CHS is a clinical diagnosis, not one made by identifying structural pathology Strong evidence[3].
Continuing cannabis while switching strains, switching to CBD-dominant products, or reducing dose — patients frequently report online that these approaches help, but published evidence does not support partial reduction as a reliable strategy. Relapse on resumption is the dominant pattern in case series Anecdote[2][5].
Mechanism and Unanswered Questions
The mechanism of CHS remains unclear No data. Leading hypotheses include [3][9]:
- Downregulation or dysfunction of CB1 receptors in the gut versus the central nervous system, producing different or opposing effects in different compartments.
- TRPV1 desensitization in response to chronic cannabinoid exposure (consistent with why acute heat and capsaicin provide relief).
- Genetic variation in cannabinoid metabolism or thermoreceptor biology — a 2022 study (Russo et al.) identified candidate variants in COMT, TRPV1, CYP2C9, and other genes, but findings are preliminary and require replication Weak / limited[10].
We do not know:
- Why only some heavy cannabis users develop CHS while most do not — the prevalence in chronic users is estimated at 0.3% to 6% in ED populations, but true population prevalence is unknown Weak / limited.
- Whether high-THC concentrates increase risk compared to flower — this is suspected but not well quantified.
- The true incidence and prevalence — most estimates come from ED populations and likely undercount mild or unreported cases.
- Whether CBD, specific terpene profiles, or cultivar choice matter — claims here rest on essentially no controlled evidence No data.
- Long-term gastrointestinal consequences after recovery and abstinence.
CHS vs. Cyclic Vomiting Syndrome (CVS)
CHS clinically resembles cyclic vomiting syndrome (CVS), an idiopathic condition also characterized by episodic vomiting, and the two are often confused. Key differences Strong evidence[3][11]:
| Feature | CHS | CVS (idiopathic) |
|---|---|---|
| Cannabis use history | Daily/near-daily, chronic (typically years) | Variable or absent |
| Hot bathing relief | Characteristic and reliable | Less typical |
| Tricyclic antidepressants (amitriptyline) | Limited CHS evidence | First-line prophylaxis with reasonable RCT support |
| Resolution with cannabis cessation | Yes | No |
| Age of onset | Variable, often young to middle-aged adults | Often childhood or young adulthood |
A practical diagnostic problem: many patients diagnosed with idiopathic CVS who also use cannabis may actually have CHS, and standard CVS prophylaxis (amitriptyline, topiramate) will often fail until cannabis is stopped. Conversely, assuming every cyclic-vomiting cannabis user has CHS risks missing genuine CVS, gastroparesis, or other structural or metabolic diagnoses. Careful history and response to cessation are the best diagnostic guides.
Documented Complications
CHS can cause or worsen Strong evidence[1][3]:
- Severe dehydration and acute kidney injury (sometimes reported as "cannabinoid hyperemesis acute renal failure").
- Hypokalemia and other electrolyte disturbances, with risk of cardiac arrhythmias in severe cases.
- Burns from compulsive hot bathing, sometimes requiring hospitalization.
- Dental erosion from repeated gastric acid exposure during vomiting.
- Mallory-Weiss tears and esophagitis from forceful vomiting.
- Death — rare but reported, typically as a consequence of unmanaged electrolyte disturbances or dehydration Weak / limited[1].
The syndrome is reversible: symptoms resolve fully after cessation and do not recur (unless cannabis is reintroduced). The main clinical challenge is that cessation is difficult for many patients, particularly those who used cannabis for anxiety, pain, or sleep and fear symptom recurrence. A harm-reduction conversation that acknowledges this struggle — rather than a moralizing one — tends to improve outcomes.
Related Topics
See also: Cannabis and Irritable Bowel Syndrome, Cannabis Withdrawal Syndrome, Cannabis and Chemotherapy-Induced Nausea and Vomiting, Cannabis and Polypharmacy Risks.
Sources
- Reported Nourbakhsh M, Miller A, Gofton J, et al. Cannabinoid hyperemesis syndrome: reports of fatal cases. Journal of Forensic Sciences, 2019; 64(1): 270–274.
- Peer-reviewed Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut, 2004; 53(11): 1566–1570.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. Journal of Medical Toxicology, 2017; 13(1): 71–87.
- Peer-reviewed Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clinic Proceedings, 2012; 87(2): 114–119.
- Peer-reviewed Habboushe J, Rubin A, Liu H, Hoffman RS. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. Basic & Clinical Pharmacology & Toxicology, 2018; 122(6): 660–662.
- Peer-reviewed Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clinical Toxicology, 2018; 56(1): 15–24.
- Peer-reviewed Dean DJ, Sabagha N, Rose K, et al. A pilot trial of topical capsaicin cream for treatment of cannabinoid hyperemesis syndrome. Academic Emergency Medicine, 2020; 27(11): 1166–1172.
- Peer-reviewed Ruberto AJ, Sivilotti MLA, Forrester S, et al. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized, controlled trial. Annals of Emergency Medicine, 2021; 77(6): 613–619.
- Peer-reviewed Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Current Drug Abuse Reviews, 2011; 4(4): 241–249.
- Peer-reviewed Russo EB, Spooner C, May L, Leslie R, Whiteley VL. Cannabinoid hyperemesis syndrome survey and genomic investigation. Cannabis and Cannabinoid Research, 2022; 7(3): 336–344.
- Peer-reviewed Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society. Neurogastroenterology & Motility, 2019; 31 Suppl 2: e13604.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Chemotherapy-Induced Nausea and Vomiting — Synthetic THC drugs treat refractory CINV, but modern antiemetics remain first-line. Smoke...
- Cannabis and Irritable Bowel Syndrome — Weak evidence for symptom relief; stronger evidence for risks in chronic use.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis Withdrawal Syndrome — Real but not life-threatening withdrawal after heavy regular cannabis use.